Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase NA 7Phase 3 4Phase 4 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3

Conditions

Paraproteinemias 2Immunoglobulin Light-chain Amyloidosis 2Papillomavirus Infections 1Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Clinical Protocols × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT06281119 2025-01-07

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Serum Institute of India Pvt. Ltd.

Phase 3 Not yet recruiting
450 enrolled

Papillomavirus Infections

NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown
4,420 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡